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To the Editor:
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a
single nucleotide mutation in the β-globin gene leading to the produc-
tion of an abnormal hemoglobin S (HbS). When HbS becomes deoxy-
genated it polymerizes, deforming the red blood cells (RBCs) into a
curved or sickle shape. Sickle RBCs are rigid and poorly deformable, and
together with other abnormalities, block the microvasculature, causing
painful vaso-occlusive crises (VOC), the hallmark complication of SCD.
Hemolysis, increased RBC adhesion, endothelial dysfunction, inflamma-
tion, oxidative stress, and hemostatic activation, also contribute to the
development of VOC,1 although their relative contribution remains
subject to debate. The non-RBC factors are found in other disease
conditions, yet no other disease is associated with VOC, highlighting
the key contribution of sickled RBCs to SCD pathophysiology.1
Oxygen gradient ektacytometry is a newly developed method that
characterizes sickling behavior.2 This functional assay measures
deformability of the total RBC population over a range of oxygen con-
centrations, providing parameters that reflect features of sickling
behavior and RBC function. The most important parameters are:
(a) EImax, RBC deformability when RBCs are fully oxygenated; (b) EImin,
lowest RBC deformability when HbS polymerization is at its peak value
due to deoxygenation; and (c) point of sickling (PoS): the oxygen tension
at which a 5% decrease in oxygenated EImax is observed during the first
minutes of deoxygenation, reflecting the patient-specific pO2 at which
HbS polymers are increasing and sickling of RBCs, that are able to
deform under normoxic conditions, begins (Figure 1E).2
Clinically relevant biomarkers are needed to serve as surrogate
endpoints to evaluate new US Food and Drug Administration (FDA)
approved therapies for SCD in subsequent clinical trials. Crizanlizumab
and L-glutamine were approved based on subjective clinical endpoints
of number of VOC or time to next VOC. No functional (sickling) assay
was included in the trial design of L-glutamine3 or crizanlizumab, and
they did not change any conventional laboratory values.4 Functional
RBC tests like oxygen gradient ektacytometry may provide quantitative,
clinically relevant biomarkers to serve as surrogate endpoints for
subsequent clinical trials and for patient care.
In this study, we initiated clinical validation studies of oxygen gradi-
ent ektacytometry-derived biomarkers by investigating the relationship
between these biomarkers and frequency of VOC. In addition, we eval-
uated the ability of these biomarkers to detect RBC changes with initia-
tion of hydroxyurea (HU) or transfusion therapy.
A total of 126 patients were enrolled at participating sites in The
Netherlands, France or the United States (US). Peripheral blood samples
from patients with no VOC in the past 2 years (VOC-group) were com-
pared to patients who experienced one or more VOC (VOC+ group) in
the past 2 years. The VOC was defined as an acute pain event attrib-
uted to SCD requiring hospital admission, emergency room evaluation
or an unplanned visit to the outpatient clinic. The European cohort was
comprised of adult patients (n = 46) and the United States cohort con-
sisted of pediatric patients (n = 80) aged 3-18 years with HbSS, HbSβo
or HbSβ+. Characteristics of VOC+ and VOC- cohorts are shown in
Table S1. Oxygen gradient ektacytometry was performed as described
in detail elsewhere (supplemental methods).2 Overall, patient demo-
graphics and laboratory parameters were comparable between the two
cohorts with differences regarding age, percentage of patients on HU
treatment, percentage of patients on HU and chronic transfusion (CTf).
In the adult cohort, PoS differed significantly between VOC- group
(median 41.6 mm Hg) and VOC+ group (median 53.7 mm Hg, P = .001,
Figure 1A). The same was observed in the pediatric cohort (P = .0495,
Figure 1C), which indicates that RBCs of patients without VOC can
tolerate lower oxygen tensions before sickling occurs. EImin in both
cohorts was significantly lower in the VOC+ group (adult cohort
P = .0178, pediatric cohort P = .022, Figure 1B,D), which highlights the
fact that RBCs of patients in the VOC+ group are less deformable after
deoxygenation. The EImax was not significantly different between the
VOC- and VOC+ groups in the pediatric cohort, but was significantly
higher in the VOC- group in the adult cohort (Figure S1A,B).
To assess the association of oxygen gradient ektacytometry-
derived biomarkers with RBC characteristics and known indicators
of disease severity, such as HbF and HbS levels, and markers of
hemolysis (Hb, lactate dehydrogenase (LDH), bilirubin and absolute
reticulocyte count(ARC), the degree of correlation between these
laboratory parameters and PoS, EImax, EImin, were calculated for each
cohort. We found significant correlations between EImax, PoS and
EImin with HbS and HbF levels. Various biomarkers correlated with
ARC, bilirubin, LDH, ferritin, or creatinine in both cohorts (Tables S2
and S3).
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F IGURE 1 Oxygen gradient ektacytometry-derived biomarkers are associated with VOC and improve with standard of care therapy. A, Point
of Sickling (PoS) is significantly higher in patients with SCD in the adult cohort who experienced one or more VOC in the past 2 years (VOC+).
Colors show different treatment regimens: untreated (red), HU treatment (purple), chronic transfusion (blue), HU and chronic transfusion
(turquoise). B, Minimum deformability (EImin) is significantly higher in patients who did not experience a VOC in the past 2 years (VOC−)
compared to patients who did, in the adult cohort. C, PoS is significantly higher in the VOC+ group in the pediatric cohort. D, EIminis significantly
lower in the VOC+ group. The effect of starting HU therapy was measured in 15 patients with SCD at baseline, and after 1, 3 and 6 months of
HU therapy. E, Representative curve of a patient before and during hydroxyurea (HU) titration to maximum tolerated dose. F, Median values of
point of sickling (PoS) before and during HU therapy. PoS significantly decreases after 3 and 6 months compared to baseline values. G, Median
values of minimum deformability upon deoxygenation (EImin) before and during HU therapy. EIminsignificantly increases after 3 and 6 months of
HU therapy compared to baseline values. Seven patients with SCD were followed just before and after transfusion therapy. H, Median values of
PoS are significantly decreased after transfusion, compared to before transfusion values. Median values of EIminI, are significantly increased by
transfusion. Twenty-one patients with SCD were followed during HU and HU with CTf therapy. J, Median values of PoS before and on CTf that
significantly decreases during CTf. Median values of EIminK, are increased with CTf. Error bars represent interquartile range. ****P < .0001,
***P < .001, **P < .01, *P < .05
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To assess if oxygen gradient ektacytometry-derived biomarkers
changed in patients receiving or initiating standard of care treatment
of transfusion or HU, we analyzed three patient cohorts on different
treatment regimens. In the first cohort, 15 SCD patients were
followed before and during HU treatment. After 3 and 6 months on
HU the PoS decreased significantly and EImax and EImin increased
accordingly (Figure 1E-G; Figure S2; Table S4). Transfusion immedi-
ately improved EImax, PoS, and EImin, (all P < .05, Figure 1H,I,
Figure S3, Table S5). In the cohort treated with CTf, PoS, EImax and
EImin improved significantly (all P < .01, Figure 1J,K, Figure S4,
Table S5). Importantly, while oxygen gradient ektacytometry-derived
biomarkers showed a considerable and significant change, most con-
ventional laboratory tests did not (Table S5), confirming that this tech-
nique provides an additional insight into the efficacy of disease
modifying therapies.
In our study, specific oxygen gradient ektacytometry-derived bio-
markers were associated with VOC in both cohorts, in contrast to
conventional clinical laboratory parameters such as HbS and HbF
levels and ARC. The PoS and EImin were found to be the most repro-
ducible clinically relevant biomarkers because they were associated
with VOC in both adult and pediatric cohorts. The reproducible asso-
ciation observed, is likely due to the fact that oxygen gradient
ektacytometry is a functional test that captures the combined effect
of many factors contributing to RBC function, some measurable by
clinical testing, like HbF and HbS levels, and some not, like the impact
of 2,3-diphosphoglycerate levels, and oxidative stress.2
However, we observed differences in oxygen gradient
ektacytometry-derived biomarkers between cohorts. This could be due
to differences in pediatric and adult SCD pathophysiology, in particular
RBC rheological characteristics, and notably RBC deformability, which
has been found to be different between adults and young children.5 In
addition, other factors may also play a role, such as (a) differences in
access to care (US vs Europe), (b) differences in guidelines, clinical
practice and health care between adult and pediatric patients,
(c) cultural differences between sites, particularly response to pain,
(d) environmental factors such as climate, or (e) technical differences.
Limitations of oxygen gradient ektacytometry-derived biomarkers
are that they primarily evaluate RBC function, and do not capture
other factors important in SCD pathophysiology. Inclusion of other
factors, such as soluble vascular cell adhesion molecule, or other func-
tional tests, like adhesion to an artificial microfluidic network could
complement this technology.
There are four FDA approved pharmacologic therapies available
for routine SCD care in the US. The best way to choose which drug to
prescribe to which patients is a topic of intense discussion. There are
also several other agents currently in clinical trials in the US and in
Europe. Clinically relevant biomarkers, such as oxygen gradient
ektacytometry, are needed for several indications: (a) to select the
optimal therapy based on the patientʼs particular blood rheology,
according to the principles of precision medicine, (b) to monitor effi-
cacy in an objective, rapid manner rather than watching for clinical
complications which can take years to emerge, and (c) to provide
objective clinically relevant endpoints for clinical trials. Biomarkers of
RBC function, like those provided by oxygen gradient ektacytometry,
could also be excellent ways to assess gene-based therapy outcomes.
The amount of HbF induction needed to be achieved by gene therapy,
or amount of HbS reduction by allogeneic stem cell transplantation to
affect a cure is still a topic for discussion. In most clinical trials sickling
behavior is not functionally assessed, as microscopy based sickling
assays are static and do not provide information on patient specific
sickling characteristics.6 Additionally, different gene therapy trials
induce different functional hemoglobins, and a functional analysis of
the resulting RBC population is the best way to compare different
strategies head to head. The VOC is still the primary endpoint in
ongoing gene therapy trials, however lack of VOC does not demon-
strate a cure as organ damage may still be ongoing. Functional bio-
markers like EImin and PoS could better assess the effectivity of these
therapies in individual patients, indicating if the treatment was suc-
cessful enough to prevent clinically relevant sickling.7
In conclusion, oxygen gradient ektacytometry-derived biomarkers
provides functional, clinically relevant next generation biomarkers that
are associated with VOC. This can provide the clinician with information
about patient RBC characteristics and sickling propensity that could
eventually aid in clinical decision making. Moreover, oxygen gradient
ektacytometry captures several RBC characteristics that have additional
value over conventional laboratory tests. We have shown that oxygen
gradient ektacytometry-derived biomarkers improve with known effica-
cious therapies and are associated with VOC; therefore, these bio-
markers can be an objective surrogate endpoint of disease modification.
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Hepcidin levels predict Covid-
19 severity and mortality
in a cohort of hospitalized
Italian patients
To the Editor:
The hallmark of severe Covid-19, a recently described systemic dis-
ease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2),
is the acute activation of the innate immune system associated with a
prothrombotic state.1 The clinical spectrum of Covid-19 ranges from
asymptomatic cases to respiratory failure. Inflammatory cytokines,
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